CROS NT: India an 'important and strategic market'
The new office is the fourth global office established by the contract research organization (CRO) in the last six years. Other branches are located in Italy, Germany, the UK, and the US.
Andrew MacGarvey, CEO of CROS NT, told us the decision to move into India was a strategic business move that allows the company to expand its resource pool and business hours to make a team accessible, “almost 24 hours a day.”
“India is an important and strategic market for any company operating globally in the clinical trials space,” McGarvey added. “Not only is India an emerging and booming market in pharmaceuticals and drug development, but it is also home to large pool of talented resources in data services … as well as clinical operations and monitoring.”
Initially, the facility will offer statistical programming, database programming, and certain pharmacovigilance services; however, all of the company’s services will eventually be available.
MacGarvey said the company will work alongside its Indian colleagues to bring its risk-based monitoring and centralized statistical monitoring solutions to its customers.
“CROS NT is always looking to expand both geographical and in terms of our product and services portfolio,” he added. Geographically, the company is looking to further explore the Asia-Pacific market, which MacGarvey said “has a wealth of resources and is a crucial hub for clinical trials.”
“As we expand our clinical, regulatory and data services lines we will see a need for geographic expansion to meet the resourcing demands and the needs to be closer to our client base,” he added. “Therefore, we will probably see further expansion in North America and Asia-Pacific.”
